Table 1.
Participant demographics
| Number of participants | |
| S-warfarin | 306 |
| R-warfarin | 309 |
| S-warfarin plasma concentrations | 739 |
| R-warfarin plasma concentrations | 759 |
| Men S-warfarin | 178 (58%) |
| Men R-warfarin | 181 (59%) |
| Age, mean (range) (years) | 66.4 (19–95) |
| Bodyweight, mean (range) (kg) | 80.7 (36–172) |
| Co-medication (S-warfarin) | |
| Amiodarone Yes | 20 (6.5%) |
| Amiodarone No | 286 (93.5%) |
| CYP2C9 genotype* | |
| *1/*1 | 195 (63.7%) |
| *1/*2 | 59 (19.3%) |
| *1/*3 | 29 (9.5%) |
| *2/*2 | 1 (0.3%) |
| *2/*3 | 6 (2.0%) |
| *3/*3 | 2 (0.6%) |
| Missing | 14 (4.6%) |
| CYP2C19 genotype* (SNP rs3814637) | |
| Homozygote | 219 (70.9%) |
| Heterozygote | 25 (8.1%) |
| Mutant-type – homozygote | 4 (1.3%) |
| Missing | 61 (19.7%) |
| CYP3A4 genotype* (SNP rs2242480) | |
| Homozygote | 226 (73.1%) |
| Heterozygote | 42 (13.6%) |
| Mutant-type – homozygote | 3 (1.0%) |
| Missing | 38 (12.3%) |
*
CYP2C9 frequencies are for S-warfarin, whilst CYP2C19 and CYP3A4 frequencies apply to R-warfarin. Frequencies for nonsignificant SNPs are available but not reported.